Table 6 Predominant symptoms prior to re-irradiation and their relative improvement development during follow-up
From: Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma
Symptoms before particle re-irradiation | Symptoms at last follow-up | Clinical outcome | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Predominant clinical symptoms | low grade (CTCAE I-II) | high grade (CTCAE III or higher) | low grade (CTCAE I-II) | high grade (CTCAE III or higher) | stable or improvement | worsening | ||||||
n= | % | n= | % | n= | % | n= | % | n= | % | n= | % | |
sensory impairment | 17 | 40,5% | 1 | 2,4% | 14 | 33,3% | 1 | 2,4% | 16 | 38,1% | 1 | 2,4% |
motor impairment | 12 | 28,6% | 3 | 7,1% | 9 | 21,4% | 1 | 2,4% | 13 | 31,0% | 3 | 7,1% |
visual impairment | 11 | 26,2% | 6 | 14,3% | 7 | 16,7% | 9 | 21,4% | 12 | 28,6% | 4 | 9,5% |
cognitive impairment | 9 | 21,4% | 0 | 0,0% | 5 | 11,9% | 1 | 2,4% | 10 | 23,8% | 0 | 0,0% |
hearing impairment | 7 | 16,7% | 3 | 7,1% | 9 | 21,4% | 3 | 7,1% | 10 | 23,8% | 2 | 4,8% |
headaches | 6 | 14,3% | 0 | 0,0% | 7 | 16,7% | 0 | 0,0% | 10 | 23,8% | 2 | 4,8% |
seizures | 5 | 11,9% | 0 | 0,0% | 4 | 9,5% | 0 | 0,0% | 6 | 14,3% | 1 | 2,4% |
nausea | 4 | 9,5% | 0 | 0,0% | 3 | 7,1% | 1 | 2,4% | 8 | 19,0% | 2 | 4,8% |
dizziness | 2 | 4,8% | 1 | 2,4% | 3 | 7,1% | 1 | 2,4% | 4 | 9,5% | 2 | 4,8% |
facial pain | 2 | 4,8% | 1 | 2,4% | 3 | 7,1% | 1 | 2,4% | 4 | 9,5% | 2 | 4,8% |
fatigue | 1 | 2,4% | 0 | 0,0% | 5 | 11,9% | 0 | 0,0% | 9 | 21,4% | 2 | 4,8% |